Hosted on MSN
Amgen lifts 2026 outlook as MariTide trials expand
Amgen beat Wall Street expectations in Q1 2026 with $8.62 billion in revenue and $5.15 EPS, driven by strong growth in key drugs like Repatha and Evenity. Management raised full-year revenue and EPS ...
Zacks Investment Research on MSN
Amgen's Q1 earnings top estimates, 16 drugs deliver double-digit gains
Amgen AMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My doctor has put ...
DEAR DR. ROACH: I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol.
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...
Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...
Knee osteoarthritis is a complex disease that affects the whole joint, including bone, cartilage, ligaments and muscles. Osteoarthritis is a common cause of pain and movement difficulty, affecting 8.3 ...
MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha ® (evolocumab injection) for eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results